These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38597998)

  • 21. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
    Kros JM; Rushing E; Uwimana AL; Hernández-Laín A; Michotte A; Al-Hussaini M; Bielle F; Mawrin C; Marucci G; Tesileanu CMS; Stupp R; Baumert B; van den Bent M; French PJ; Gorlia T
    Neuro Oncol; 2023 Aug; 25(8):1443-1449. PubMed ID: 36571817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical Statistics Unlock the Gateway to Further Research: Using Deep Learning to Predict CDKN2A/B Homozygous Deletion in Isocitrate Dehydrogenase-Mutant Astrocytoma.
    Takahashi K; Usuzaki T; Inamori R
    Korean J Radiol; 2023 Dec; 24(12):1303-1305. PubMed ID: 38016690
    [No Abstract]   [Full Text] [Related]  

  • 23. A novel MRI-based deep learning networks combined with attention mechanism for predicting CDKN2A/B homozygous deletion status in IDH-mutant astrocytoma.
    Zhang L; Wang R; Gao J; Tang Y; Xu X; Kan Y; Cao X; Wen Z; Liu Z; Cui S; Li Y
    Eur Radiol; 2024 Jan; 34(1):391-399. PubMed ID: 37553486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
    Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
    Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial for "Preoperative Discrimination of CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytoma: A Deep Learning-Based Radiomics Model Using MRI".
    Gumeler E; Karli Oguz K
    J Magn Reson Imaging; 2024 May; 59(5):1665-1666. PubMed ID: 37306402
    [No Abstract]   [Full Text] [Related]  

  • 26. Utility of real-time polymerase chain reaction for the assessment of CDKN2A homozygous deletion in adult-type IDH-mutant astrocytoma.
    Shimizu Y; Suzuki M; Akiyama O; Ogino I; Matsushita Y; Satomi K; Yanagisawa S; Ohno M; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Kondo A
    Brain Tumor Pathol; 2023 Apr; 40(2):93-100. PubMed ID: 36788155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
    Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
    Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative Discrimination of CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytoma: A Deep Learning-Based Radiomics Model Using MRI.
    Gao J; Liu Z; Pan H; Cao X; Kan Y; Wen Z; Chen S; Wen M; Zhang L
    J Magn Reson Imaging; 2024 May; 59(5):1655-1664. PubMed ID: 37555723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitotic index is (still) important for grading isocitrate dehydrogenase (IDH)-mutant astrocytoma.
    Roberts KF; Dahiya SM
    Neuro Oncol; 2023 Aug; 25(8):1450-1451. PubMed ID: 37097042
    [No Abstract]   [Full Text] [Related]  

  • 30. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
    Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK
    Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas.
    Sahm F; Korshunov A; Schrimpf D; Stichel D; Jones DT; Capper D; Koelsche C; Reuss D; Kratz A; Huang K; Wefers AK; Schick M; Bewerunge-Hudler M; Mittelbronn M; Platten M; Hänggi D; Jeibmann A; Unterberg A; Herold-Mende C; Pfister SM; Brandner S; Wick W; von Deimling A
    Acta Neuropathol; 2017 Feb; 133(2):325-327. PubMed ID: 28000032
    [No Abstract]   [Full Text] [Related]  

  • 32. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
    Yoda RA; Marxen T; Longo L; Ene C; Wirsching HG; Keene CD; Holland EC; Cimino PJ
    J Neuropathol Exp Neurol; 2019 Nov; 78(11):1002-1010. PubMed ID: 31529048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
    Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
    Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of CDKN2A deletion in grade 2/3 IDH-mutant astrocytomas: need for selective approach in resource-constrained settings.
    Suman S; Sharma R; Katiyar V; Mahajan S; Suri A; Sharma MC; Sarkar C; Suri V
    Neurosurg Focus; 2022 Dec; 53(6):E17. PubMed ID: 36455270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated molecular characterization of IDH-mutant glioblastomas.
    Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to "Medical Statistics Unlock the Gateway to Further Research: Using Deep Learning to Predict CDKN2A/B Homozygous Deletion in Isocitrate Dehydrogenase-Mutant Astrocytoma".
    Park YW; Han K; Kim SH
    Korean J Radiol; 2023 Dec; 24(12):1306-1308. PubMed ID: 38016689
    [No Abstract]   [Full Text] [Related]  

  • 37.
    Richardson TE; Walker JM
    Clin Neuropathol; 2021; 40(4):209-214. PubMed ID: 33560216
    [No Abstract]   [Full Text] [Related]  

  • 38. Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.
    Takami H; Mukasa A; Takayanagi S; Koike T; Matsuura R; Ikemura M; Ushiku T; Yoshikawa G; Shibahara J; Tanaka S; Saito N
    Brain Tumor Pathol; 2023 Jan; 40(1):26-34. PubMed ID: 36572828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved grading of IDH-mutated astrocytic gliomas.
    Pirozzi CJ; Yan H
    Nat Rev Neurol; 2018 Jul; 14(7):383-384. PubMed ID: 29855600
    [No Abstract]   [Full Text] [Related]  

  • 40. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
    Ammendola S; Broggi G; Barresi V
    Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.